About us

The new coronavirus infection, which originated in Wuhan, China, has caused a global pandemic and many people have lost their lives. The world has changed, and society’s needs are changing rapidly. The whole world is in an unprecedented state, and our lifestyle has been revolutionized. Many socioeconomic activities have become remote, and the economic activities are dramatically changing due to restrictions on people's movements and activities. Even if the current restrictions become more relaxed and end, it is unlikely that our lifestyle of working remotely and maintaining social distance as much as possible will return to exactly the same as it was before. In addition, the fight against infectious diseases is also a fight against evolution due to mutation of pathogens. As seen in the new coronavirus, mutation increases the infectivity of pathogens and gains characteristics to avoid neutralizing antibodies (ineffectiveness of vaccines), and in 2050, it is predicted that AMR (Antimicrobial Resistance) will be the top in the cause of death surpassing the cancer.

In terms of cancer treatment, advances in genomic medicine have led to the rapid development of precision medicine that selects and treats the most appropriate anti-cancer drugs, and has achieved remarkable results in the treatment of cancer. The drug resistant cancer will be our next challenge. For both infectious diseases and cancer, we have to catch up the changes in pathogens and cancer cells and develop the new diagnosis and treatment.

At the end of January 2020, when large cruise ship, the Diamond Princess, arrived at Yokohama Port with infected passengers, the situation turned into a battlefield, and Governor Kuroiwa of Kanagawa Prefecture made an urgent request for our company to immediately create a diagnostic kit. Even at this time, in order to respond to the sudden emergence of a large social need, we completed the kit within two weeks and began manufacturing and supplying it.

The necessity and urgency of social needs are changing drastically due to these unexpected changes in society and the global environment, and we believe that it is our mission to respond to these changes in a timely manner. With the spirit of Never Give Up, we will do our best to meet the needs of society.

Yoshihide Hayashizaki

Representative CEO, K.K. DNAFORM, Representative CEO, K.K. Mirai Genomics, 　
Chairman & CEO, K.K. SS Dnaform
2-6-29 Tsurumi-chuo, Tsurumi-ku, Yokohama, Kanagawa, 230-0051, Japan
Phone: +81-45-510-0607
Fax: +81-45-510-0608
e-mail：yoshihide.hayashizaki@dnaform.jp

EDUCATION

1982 M.D. Medical faculty of Osaka University, Japan
1986 Ph.D. Osaka University, Institute for Molecular and Cellular Biology, Japan

MAJOR EMPLOYMENT

1995-1998 Project Director, RIKEN genome exploration research project, Japan
1995-2008 Chief Scientist, Department Director and Chairman, Genome Science Laboratory, RIKEN, Japan
1998-2008 Project Director, RIKEN Genome Exploration Research Group, Genomic Sciences Center, Japan
2008-2013 Director, Omics Science Center, RIKEN Yokohama Institute, Japan
2013-2021 Program Director, RIKEN Preventive Medicine and Diagnosis Innovation Program, Japan
2015-2018 Advisor to President, RIKEN
2016-2021 Core Principal Investigator, RIKEN
2021-present Representative CEO, K.K. Mirai Genomics, K.K. DNAFORM, Chairman & CEO, K.K. SS Dnaform

POSITIONS

1995-2010 Professor, Tsukuba University Medical School
1998-2013 Professor, Graduate school of Integrated Science, Yokohama City University, Japan
2003-2009 Guest Professor, University of Queendland, Australia
2003-2011 Guest Professor, Karolinska Institute, Sweden
2011-present Scientific Advisory Board Member, Science for Life Laboratory (SciLifeLab), Sweden
2012-2013 Visiting Scholar, Beijing Genomics Institute (BGI), China
2012-2015 Board of Trustees, BioBank Qatar, Qatar
2015-present International Scientific Advisory Committee, (ISAC),Qatar
2015-present Visiting Professor, Juntendo University, Japan
2015-present Executive Director, The Japan China Medical Association, Japan
2015-present Distinguished visiting professor, University at Buffalo, the State University of New York, USA
2016-2018 Senior Researcher, Research Institute at SFC, Keio University, Japan
2017-present Committee member, The Japan China Medical Association, Japan, Cooperation Committee
2018-present Auditor-secretary, Association for Rare Variant Surveillance（RVS)
2019-2019 Part-time professor, Kyoto University, Japan

AWARDS

1995 Tokyo Techno forum Gold Medal Prize, Japan
2000 Tsukuba Prize, Japan
2004 Commendation by the Minister of Education, Culture, Sports, Science and Technology Japan
2005 NISTEP AWARD 2005, Japan
2007 Medal with Purple Ribbon, Japan
2010 Kihara Prize, The Genomics Society Japan
2010 Mochida Commemoration Science Prize, Japan
2012 Honorary Doctor of Medicine (MDhc), Karolinska Institute (Sweden)
2013 Chen Award for Distinguished Academic Achievement in Human Genetic and Genomic
Research（Human Genome Organization: HUGO）
2016 The Australian Museum, 2016 Eureka Prize for Excellence in International Scientific Collaboration (Australia)
2017 Symbol of Trust, EIDOS-MEDICINE (Russia)
2017 The 58th Science and Technology Firm Festival, Excellence Award, Scientific Frontier, Unlocking the Mysteries of Life with RNA
2019 EMBO Associate Member

QUALIFICATIONS

Major international experience:

  • General organizer of the international FANTOM1-5 consortium

Major scientific achievements:

  • Development of a series of cDNA technologies and its application to establish a mouse genome encyclopedia.
  • Development of Cap Analysis of Gene Expression (CAGE), gene expression profiling method.
  • Leading scientist in omics science

SELECTED PEER-REVIWED PUBLICATIONS (Selected from 575 publications)

  1. Kawai J, et al. Functional annotation of a full-length mouse cDNA collection. Nature, 409, 685-690 (2001)
  2. Okazaki Y, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature, 420, 563-73 (2002)
  3. Carninci P, et al. The transcriptional landscape of the mammalian genome. Science, 309, 1559-1563 (2005)
  4. Katayama S, et al. Antisense transcription in the mammalian transcriptome. Science, 309, 1564-1566 (2005)
  5. Carninci P. et al. Genome-wide analysis of mammalian promoter architecture and evolution. Nature Genetics, 38, 626-635 (2006)
  6. Suzuki H, et al. The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nature Genetics, 41, 553-62 (2009)
  7. Y. Maida, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature, 461, 230-235 (2009).
  8. Ravasi T, et al. An atlas of combinatorial transcriptional regulation in mouse and man. Cell, 140, 744-752 (2010)
  9. Forrest AR, et al. A promoter-level mammalian expression atlas. Nature, 507, 462-470 (2014)
  10. Andersson R, et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455-461 (2014)
  11. Arner E. et al. Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells, Science, 347, 1010-1014 (2015)
  12. Rackham, O.J. et al.　A predictive computational framework for direct reprogramming between human cell types. Nat Genet, 48, 331-335(2016).
  13. Chung-Chau Hon, et al. An atlas of human long non-coding RNAs with accurate 5’ ends. Nature, 543, 199-204(2017)
  14. Derek de Rie, et al. The FANTOM5 integrated expression atlas of miRNAs and their promoters.
    Nature Biotechnology (2017)
  15. Hirabayashi, et al. NET-CAGE characterizes the dynamics and topology of human transcribed cis-regulatory elements. Nat Genet, 51, 1369-1379(2019)

See also http://fantom.gsc.riken.jp/papers/